Bellicum Pharmaceuticals Inc (STU:BPXA)
€ 0.0635 0 (0%) Market Cap: 617,000.00 Enterprise Value: -4.92 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q4 2018 Bellicum Pharmaceuticals Inc Earnings Call Transcript

Mar 12, 2019 / 09:00PM GMT
Release Date Price: €28.8 (+11.20%)
Operator

Ladies and gentlemen, greetings, and welcome to the Bellicum Pharmaceuticals Fourth Quarter and Full Year 2018 Financial Results. (Operator Instructions) As a reminder, this program is being recorded.

It is now my pleasure to introduce your host, Atabak Mokari, Chief Financial Officer. Thank you. You may begin.

Atabak Mokari
Bellicum Pharmaceuticals, Inc. - CFO

Thank you. Good afternoon, everyone, and thank you for joining the call. With me today is Rick Fair, Bellicum's President and Chief Executive Officer; Bill Grossman, Chief Medical Officer; and Aaron Foster, Head of Research.

Earlier this afternoon, Bellicum released financial results for the fourth quarter and full year ended December 31, 2018. If you have not received this release or if you would like to be added to the distribution list, you can do so on the Investor Relations page of the company's website.

As a reminder, today's conference call will include forward-looking statements made under the Private Securities Litigation Reform Act of 1995, including statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot